Kadar Plasma Epstein-Barr Virus (EBV) DNA sebagai Parameter Prognosis pada Kanker Nasofaring Tidak Berkeratin

Sinta Prastiana Dewi, - Handoko, Marlinda Adham Yudartho, Soehartati Argadikoesoema Gondhowiardjo

Sari


Kanker Nasofaring (KNF) merupakan keganasan yang sering ditemukan di Asia.1 Puncak insidensi KNF berada pada usia dewasa muda dan pada pasien usia 55 – 59 tahun.2 Radioterapi merupakan terapi standar untuk KNF stadium awal, sedangkan pada stadium lokal lanjut diberikan kemoradiasi.1 KNF telah terbukti memiliki keterkaitan dengan Epstein Barr Virus (EBV). Dengan berkembangnya biologi molekular, konsentrasi DNA tumor dalam plasma dan serum pada pasien KNF dapat diukur secara kuantitatif dengan polymerase chain reaction (PCR).3 Plasma EBV DNA berguna dalam hal diagnosis, pemantauan respon terapi, dan prediktor prognosis pada pasien KNF.1,3 Penulisan tinjauan pustaka ini ditujukan untuk menambah pengetahuan mengenai manfaat pemeriksaan kadar plasma EBV DNA pada pasien KNF.


Kata Kunci


Epstein Barr Virus, DNA EBV, kanker nasofaring

Teks Lengkap:

PDF

Referensi


Lee VHF, Kwong DLW, Leung TW, Choi CW, Lam KO, Sze CK, et al. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma q. Clin Oncol. 2016;28:42–9.

Studiengruppe JEDG. Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents – Recommendations of the GPOH-NPC Study Group. Klin Padiatr. 2016;228(03):105–12.

Peng H, Guo R, Chen L, Zhang Y, Li W, Mao Y, et al. Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. Sci Rep. 2016;6:22000(October 2015):1–9.

International Agency for Research on Cancer. Cancer Today [Internet]. 2018 [cited 2020 Jun 29]. Available from: https://gco.iarc.fr/

Perez CA, Halperin EC, Wazer DE, Brady LW. Principles and Practice Radiation Oncology. Sixth edit. Philadelphia; 2013. 732 p.

Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24.

Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, et al. Head and Neck Cancers. NCCN Clin Pract Guidel Oncol. 2019;3.

Lee AWM, Zong JF, Pan JJ, Choi HCW, Sze HCK. Staging of Nasopharyngeal Carcinoma Based on the 8th Edition of the AJCC / UICC Staging System. Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. Elsevier; 2019. 179–203 p.

Wang W, Lin T, Twu C, Tsou H, Lin P, Liu Y, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA. Oncotarget. 2016;7(27).

Cohen JI. Epstein - Barr Virus Infection. N Engl J Med. 2000;343:481–92.

Argadikoesoema SG. Faktor prediksi respons radiasi pada karsinoma nasofaring : tinjauan khusus pada aktivitas proliferasi dan ekspresi epstein barr virus-latent membrane protein 1. University of Indonesia; 1998.

Kimura H, Kawada J-I, Ito Y. Epstein-Barr Virus-Associated Lymphoid Malignancies: The Expanding Spectrum of Hematopoietic Neoplasm. Nagoya J Med Sci. 2013;75:169–79.

Tsao SW, Tsang CM, Lo KW. Epstein – Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc London Ser B, Biol Sci. 2017;327(1732):20160270.

Dermime S. Role of Epstein – Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target. Front Oncol. 2018;8(July):1–14.

Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol. 2000 Oct 1;53(5):238 LP – 247.

Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol Mol Pathol. 2000;53(5):248–54.

Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein–Barr virus. Semin Cancer Biol. 2014;1–9.

Lo YMD, Chan LYS, Lo K, Leung S, Zhang J, Chan ATC, et al. Advances in Brief Quantitative Analysis of Cell-free Epstein-Barr Virus DNA in Plasma of Patients with Nasopharyngeal Carcinoma 1. Cancer Res. 1999;1188–91.

Yip TTC, Ngan RKC, Fong AHW, Law SCK. Application of circulating plasma / serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014;50(6):527–38.

Chen W-H. Prognostic Value of Plasma Epstein – Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent. Medicine (Baltimore). 2016;95(5):7–11.

Lertbutsayanukul C, Kannarunimit D, Prayongrat A, Chakkabat C, Kitpanit S, Hansasuta P. Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy. Radiol Oncol. 2018;52(2):195–203.

Adham M, Greijer AE, Verkuijlen SAWM. Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment. 2013;

Gondhowiardjo S. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:323—331.

Gondhowiardjo SA, Adham M, Kodrat H, Tobing DL, Haryoga IM, Dwiyono AG, et al. Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer. World J Oncol. 2019 Oct;10(4–5):157–61.

Gondhowiardjo SA, Handoko, Adham M, Rachmadi L, Kodrat H, Tobing DL, et al. Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer. PLoS One. 2020;15(3):1–10.




DOI: https://doi.org/10.32532/jori.v11i1.107 <

Article metrics

Abstract views : 22 | views : 16

Refbacks

  • Saat ini tidak ada refbacks.


  

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.